Abstract
The Fas-Fas ligand system is important for apoptosis of activated immune cells. Perturbation of this system occurs in diseases with dysregulated inflammation. Increased soluble Fas (sFas) occurs in systemic inflammatory response syndrome (SIRS) and can block apoptosis. Increased shedding of FasL (sFasL) occurs in viral infection and hepatitis. Although dysregulated inflammation is associated with sepsis-induced multiple organ failure (MOF) in children, a role for Fas has not been established. We hypothesize that 1) sFas will be increased in children with severe and persistent sepsis-induced MOF and will correlate with inflammatory markers suggesting a role for sFas in inflammatory dysregulation in severe sepsis, and 2) sFasL will be increased when viral sepsis or sepsis-induced liver failure–associated MOF is present in children. Plasma sFas, sFasL, IL-6, IL-10, nitrite + nitrates, and organ failure scores were measured on d 1 and d 3 in 92 children with severe sepsis and 12 critically ill control children. sFas levels were increased in severe sepsis, continued to increase in persistent MOF and nonsurvivors, and were correlated with serum inflammatory markers (IL-6, IL-10, nitrite + nitrate levels). In contrast, sFasL was not increased in severe sepsis and did not correlate with inflammation. sFasL was, however, increased in liver failure–associated MOF and in nonsurvivors, and was associated with viral infection. At autopsy, hepatocyte destruction and lymphocyte infiltration were associated with increased sFas and sFasL levels. sFas may interfere with activated immune cell death and contribute to dysregulation of inflammation, worsening outcome from severe sepsis. sFasL may contribute to hepatic injury and the development of liver failure–associated MOF.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- MAP:
-
mean arterial pressure
- MOF:
-
multiple organ failure
- OFI:
-
organ failure index
- DIC:
-
disseminated intravascular coagulation
- PMOF:
-
persistent multiple organ failure
- sFas:
-
soluble Fas
- sFasL:
-
soluble Fas ligand
- FasL:
-
Fas ligand
- NMOF:
-
no multiple organ failure
- NK:
-
natural killer cells
- SMOF:
-
sequential multiple organ failure
- SLE:
-
systemic lupus erythematosus
- TNF:
-
tumor necrosis factor
- AICD:
-
activated immune cell death
- EBV:
-
Epstein-Barr virus
- SIRS:
-
systemic inflammatory response syndrome
References
Lynch DH, Ramsdell F, Alderson MR 1995 Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 16: 569–574
Green DR, Scott DW 1994 Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 6: 476–487
Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J 1995 Regulation of apoptosis in immune cells. J Clin Immunol 15: 1–16
Nagata S, Golstein P 1995 The Fas death factor. Science 267: 1449–1456
Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N 1994 Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84: 1201–1208
Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ 1996 Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184: 429–440
Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC 1997 Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 185: 1511–1516
Mangan DF, Welch GR, Wahl SM 1991 Lipopolysaccharide, tumor necrosis factor-, and IL-1 prevent programmed cell death (apoptosis) in human peripheral blood monocytes. J Immunol 146: 1541–1546
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD 1994 Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762
Mountz JD, Zhou T, Bluethmann H, Wu J, Edwards CK 1994 Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol 1: 321–342
Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, Marshall JC 1997 Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 132: 1263–1267
Chitnis D, Dickerson C, Munster AM, Winchurch RA 1996 Inhibition of apoptosis in polymorphonuclear neutrophils from burn patients. J Leukoc Biol 59: 835–839
Mountz JD, Baker TJ, Bocherding DR, Bluethmann H, Zhou T, Edwards CK 1995 Increased susceptibility of fas mutant MRL-1pr/1pr mice to staphylococcal enterotoxin B-induced septic shock. J Immunol 155: 4829–4837
Doughty LA, Kaplan SS, Carcillo JA 1996 Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 24: 1137–1143
Doughty LA, Carcillo JA, Kaplan SS, Janosky J 1998 Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis. Crit Care Med 26: 157–162
Doughty L, Carcillo JA, Kaplan SS, Janosky J 1998 The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest 113: 1625–1631
Endo S, Inada K, Takakuwa T, Kasai T, Yamada Y, Wakabayashi G, Niimi M, Suzuki T, Taniguchi S 1996 Nitrite/nitrate (NOx) and sFas antigen levels in patients with multiple organ failure. Res Commun Mol Pathol Pharmacol 92: 253–256
Papathanassglou ED, Moynihan JA, Vermillion DL, McDermott MP, Ackerman MH 2000 Soluble Fas levels correlate with multiple organ dysfunction severity, survival, and nitrate levels, but not with cellular apoptotic markers in critically ill patients. Shock 14: 107–112
Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S 1997 Membrane Fas ligand kills peripheral blood T lymphocytes, and soluble fas ligand blocks the killing. J Exp Med 186: 2045–2050
Tanaka M, Itai T, Adachi M, Nagata S 1998 Down regulation of fas ligand by shedding. Nat Med 4: 31–36
Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J 1998 Conversion of membrane bound fas (CD95) ligand to its soluble form is associated with down regulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205–1213
Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S 1997 Lethal effects of recombinant human Fas ligand in mice treated with Propionibacterium acnes. J Immunol 158: 2303–2309
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S 1993 Lethal effect of the anti-fas antibody in mice. Nature 364: 806–809
Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata 1996 Fas ligand in human serum. Nat Med 2: 317–322
Ryo K, Kamogawa Y, Yamauchi K, Hayashi N 1996 Involvement of Fas and Fas ligand in case of fulminant hepatitis. Nippon Rinsho 54: 1965–1969
Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S 1997 Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3: 409–413
Bone RC, Fischer CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA 1989 Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389–393
Wilkinson JD, Pollack MM, Ruttiman UE, Glass NL, Yeh TS 1986 Outcome of pediatric patients with multiple organ system failure. Crit Care Med 14: 271–274
Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M 1996 Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 109: 1033–1037
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR 1982 Analysis of nitrate, nitrite, and 15N nitrate in biological fluids. Ann Biochem 126: 131–138
Niitsu N, Sasaki K, Umeda M 1999 A high serum soluble fas/APO-1 is associated with a poor outcome of aggressive non-Hodgkins lymphoma. Leukemia 13: 1434–1440
Munker R, Midis G, Owen-Schaub L, Andreff M 1996 Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 10: 1531–1533
Hori Y, Wada H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Nishiik Tamaki S, Nishikawa M, Deguchi K, Minami N, Shiku H 1999 Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation. Am J Hematol 61: 21–25
Al-Maini M, Mountz J, Al-Mohri H, El-Ageb E, Al-Riyami B, Svenson K, Zhou T, Richens E 2000 Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9: 132–139
Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M 1998 Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29: 517–523
Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P 1996 Systemic injection of a tripeptide inhibits the intercellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 184: 2067–2072
Rodriquez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli P 1996 A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 183: 1031–1036
Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteau A, Henrion A, Bluscary D, Varlet P, Joulin V, Kahn A 1996 Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 2: 80–86
Kosai K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T 1998 Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 244: 683–690
Chung CS, Xu YX, Wang W, Chaudry IH, Ayala A 1998 Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis?. Arch Surg 133: 1213–1220
Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K 1997 A metalloproteinase inhibitor prevents lethal acute graft versus host disease in mice. Blood 90: 542–548
Hasegawa D, Kojima S, Tatsumi E, Hayakawa A, Kosaka Y, Nakamura H, Sako M, Osugi Y, Nagata S, Sano K 1998 Elevation of serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood 91: 2793–2799
Author information
Authors and Affiliations
Additional information
Supported in part by MM301GCRC.
Rights and permissions
About this article
Cite this article
Doughty, L., Clark, R., Kaplan, S. et al. sFas and sFas Ligand and Pediatric Sepsis-Induced Multiple Organ Failure Syndrome. Pediatr Res 52, 922–927 (2002). https://doi.org/10.1203/00006450-200212000-00018
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200212000-00018
This article is cited by
-
Machine learning derivation of four computable 24-h pediatric sepsis phenotypes to facilitate enrollment in early personalized anti-inflammatory clinical trials
Critical Care (2022)
-
Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype
Critical Care (2017)
